Back to Health

What Is Bictegravir and What Is It For?

What Is Bictegravir and What Is It For?
Bareback Guide 14 May 2026

Bictegravir is an integrase strand transfer inhibitor and a component of one of the most widely prescribed HIV regimens in the UK. Unusually, it exists in only one product and is never prescribed separately.

What kind of drug is it?

An integrase inhibitor, the newest of the main antiretroviral classes and the one that now dominates first-line treatment. It is closely related to dolutegravir, sharing both mechanism and much of its molecular structure.

How does it work?

To establish an infection, HIV must insert a DNA copy of its genome into the chromosomes of the cell it has entered. The enzyme that performs this is called integrase, and the specific step bictegravir blocks is called strand transfer.

What happens when integration is blocked?

The viral DNA remains loose in the cell, unable to direct the production of new virus, and is eventually degraded. The infection never becomes established in that cell. Because integration is essential and irreversible, it is an effective point to intervene.

Why is integration a good target?

Because human cells have no equivalent enzyme, so a drug that blocks it can be highly specific with few effects on normal cellular processes. That specificity is a large part of why integrase inhibitors are so well tolerated.

What is it used for?

HIV treatment, within a single tablet combining bictegravir, emtricitabine and tenofovir alafenamide, branded Biktarvy. It is used both for people starting treatment and for people switching from another regimen.

Why only one product?

Commercial rather than clinical. It was developed as part of a specific single-tablet regimen and has not been made available separately or in other combinations. That limits flexibility compared with dolutegravir, which appears in several products.

Does it need a booster?

No, and this is one of its main advantages. Unlike protease inhibitors, it maintains useful levels for a full day without anything to slow its breakdown, which avoids the extensive interaction problems that boosters create.

What is its resistance barrier?

High, comparable to dolutegravir. Treatment-emergent resistance is rare even in people who do not fully suppress, which is a substantial advantage over older classes and over the earlier integrase inhibitors.

How quickly does it work?

Rapidly. Integrase inhibitors reduce viral load faster than older classes, and many people reach undetectable levels within a few weeks of starting.

Does it cover hepatitis B?

Bictegravir does not, and the tablet it comes in does, through its emtricitabine and tenofovir alafenamide components. That combination makes it suitable for people with both infections, and it means stopping cannot be casual.

Where does it sit in current practice?

First-line for many people starting treatment, and a common switch option. Its main limitations are that it comes only in one fixed combination and is not suitable where kidney or liver function is severely impaired.

Where does it sit against the alternatives?

Very close to dolutegravir in most respects. The choice frequently comes down to which combination tablet suits the rest of your situation rather than to a difference between the two drugs.

Is it a lifelong medicine?

HIV treatment is taken indefinitely rather than for a course, because stopping allows the virus to rebound within weeks. What people take does change over the years, as better options appear and as circumstances shift, so being on bictegravir now does not mean being on it forever.

Does it work if you take it properly?

For the great majority of people, yes. Modern combinations containing bictegravir achieve an undetectable viral load in most people who take them consistently, and once suppression is sustained, HIV is not passed on sexually.

Who chooses your regimen?

A clinician, with you. The clinical constraints are fixed and within them your preferences are legitimate: tablet size, dosing schedule, side effects you would rather not have, and how a regimen fits the way you actually live.

What should you ask at the start?

What this regimen requires of you daily, what side effects are common in the first month, what to do about a missed dose, and what the alternatives would be if it does not suit. Asking those four things at the outset saves a good deal later.